TRiCares develops a catheter‑based tricuspid valve replacement system designed to treat severe tricuspid regurgitation without open‑heart surgery. By leveraging minimally invasive technology, the platform aims to provide a safer, quicker option for patients who currently have limited treatment choices, targeting a growing market of millions affected by tricuspid valve disease worldwide.
Funding
Funding not disclosed
Founders
Product
Problem
Severe tricuspid regurgitation (TR) affects millions of patients worldwide, yet effective minimally invasive treatments are scarce, forcing most patients to undergo high‑risk open‑heart surgery.
Solution
TRiCares has developed a catheter‑based tricuspid valve replacement system, branded Topaz, that can be implanted percutaneously without the need for sternotomy. The device combines a self‑expanding prosthetic valve with a dedicated delivery catheter engineered for precise positioning and rapid deployment. Its unique design incorporates features that enhance anchoring stability and minimize paravalvular leak, while allowing the procedure to be performed in a catheterization laboratory under fluoroscopic guidance. By eliminating open surgery, the system reduces procedural trauma, shortens hospital stays, and expands treatment eligibility to patients who are otherwise inoperable. Clinical programs (TRICURE) are underway to validate safety and efficacy across Europe and the United States.
Target Audience
Primary customers are interventional cardiologists, cardiac surgeons, and heart‑failure centers seeking minimally invasive solutions for patients with severe tricuspid regurgitation.
Features
- Self‑expanding tricuspid prosthesis sized for the right‑sided annulus, providing full hemodynamic competence
- Dedicated low‑profile delivery catheter with intuitive control for accurate valve positioning
- Integrated anchoring mechanism that secures the valve without extensive radial force, reducing risk of annular injury
- Designed for rapid implantation, enabling procedure times comparable to other transcatheter valve therapies
- Strong intellectual‑property portfolio protecting the valve architecture and delivery system
- Compatibility with standard catheterization lab imaging and equipment, facilitating adoption in existing interventional suites